Document Detail

The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study.
MedLine Citation:
PMID:  15043515     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: By temporarily suppressing the immune response, the anti-tumour necrosis factor agent, infliximab, may increase the risk of peri-operative complications. AIM: To test this hypothesis for intestinal resection in a cohort of 313 Crohn's disease patients treated with infliximab. Forty received one or more infusions prior to intestinal resection (31/40 within 12 weeks). METHODS: The post-operative events of these patients were compared with those of a control group (infliximab naive) of 39 patients adjusted for age, gender and surgical procedure. Early (10 days) and late (3 months) major or minor complications were identified. RESULTS: The incidence of early minor (15.0% vs. 12.8%) and major (12.5% vs. 7.7%) and late minor (2.5% vs. 5.1%) and major (17.5% vs. 12.8%) complications and the mean hospital stay after surgery (10.3 +/- 4.0 days vs. 9.9 +/- 5.5 days) were similar in both groups. A trend towards an increased early infection rate was found in infliximab pre-treated patients (6 vs. 1; P = 0.10), but more patients in this group received corticosteroids and/or immunosuppressives (29 vs. 16 patients; P < 0.05). CONCLUSION: The use of infliximab before intestinal resection does not prolong the hospital stay and does not increase the rate of post-operative complications.
L Marchal; G D'Haens; G Van Assche; S Vermeire; M Noman; M Ferrante; M Hiele; M Bueno De Mesquita; A D'Hoore; F Penninckx; P Rutgeerts
Related Documents :
10400415 - Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage c...
19078465 - Mycobacterium avium/mycobacterium intracellulare complex-associated arthritis masquerad...
23236315 - Cervical artificial disc replacement versus fusion in the cervical spine: a systematic ...
23327295 - Haloperidol prophylaxis in critically ill patients with a high risk for delirium.
18351365 - Outcome in neonates with esophageal atresia treated over the last 20 years.
21561545 - Clinical outcome of diabetic peritoneal dialysis patients and evaluation of factors aff...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  19     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-03-26     Completed Date:  2004-07-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  749-54     Citation Subset:  IM    
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / adverse effects*
Cohort Studies
Crohn Disease / surgery*
Gastrointestinal Agents / adverse effects*
Middle Aged
Postoperative Complications / chemically induced*
Retrospective Studies
Risk Factors
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Gastrointestinal Agents; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colit...
Next Document:  Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial.